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Background: Tetracyclines are broad-spectrum antibiotics that are also used to induce gene expression using the
reverse tetracycline transactivator / tetracycline operator system (rtTA/tetO system). The system assumes that
tetracyclines have no effects on mammals. However, a number of studies suggest that tetracyclines may have
powerful anti-inflammatory effects. We report that the tetracycline, doxycycline, inhibits neutrophil (PMN) influx into
the lungs of mice treated with bacterial endotoxin (LPS).
Methods: Mice were challenged with intratracheal LPS in the presence or absence of doxycyline. bronchoalveolar
lavage cell counts and differential, total bronchoalveolar lavage protein, lung homogenate caspase-3 and tissue
imaging were used to assess lung injury. In addition, PMN chemotaxis was measured in vitro and syndecan-1 was
measured in bronchoalveolar lavage fluid.
Results: The administration of doxycycline resulted in a significant decrease in the number of bronchoalveolar
lavage PMNs in LPS-treated mice. Doxycycline had no effect on other markers of lung injury such as total
bronchoalveolar lavage protein and whole lung caspase-3 activity. However, doxycycline resulted in a decrease in
shed syndecan-1 in bronchoalveolar lavage fluid.
Conclusion: We conclude that doxycycline has an important anti-inflammatory effect that can potentially confound
the experiments in which the rtTA/tetO system is being used to study the immune response.
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One of the most important methods to investigate
mechanisms of disease is the deletion of specific genes
to perform loss-of-function experiments. However, trad-
itional “knockout” mice, in which a gene is deleted from
the onset of embryonic development, may respond to
the loss of the gene by developing compensatory
mechanisms that can confound the results of experi-
ments. In 1992, Gossen and Bujard developed a system
to activate genes in a time-specific manner—in essence,
an “on/off” switch— [1]. The system consists of two ele-
ments: the first is the tetracyclin-responsive element
(TRE), which is composed of the E. coli tet operator* Correspondence: matuteb@uw.edu
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reproduction in any medium, provided the or(tetO) fused with a minimal promoter sequence from
the CMV virus. The second element is the tetracyclin-
controlled transactivator tTA, created by fusing the E.
coli tet repressor with the activating domain of virion
protein 16 of herpes simplex virus. The key aspect of the
system is that TRE only initiates transcription when
bound to tTA, and the binding of tTA to TRE is
dependent on the presence or absence of a tetracycline.
There are two versions of the system: in the “tet-off” ver-
sion of the system, tTA binds to TRE exclusively in the
absence of a tetracycline; in the “tet-on” version of the
system, a reverse tTA (rtTA) binds to TRE exclusively in
the presence of a tetracycline (reviewed in [2]). By pla-
cing the tTA/rtTA sequence downstream from a tissue-
specific promoter; and the TRE proximal to a sequence
of interest, a tissue specific, inducible gene expression
system is generated. Commonly, doxycycline is used astd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that doxycycline has no effect of its own on the
responses of the model being studied.
Doxycycline is a member of the tetracycline family of
broad spectrum antibiotics (reviewed in [3]). Discovered
in the 1940s, this family is characterized by molecules
composed of a linear fused tetracyclic nucleus to which
a number of functional groups have been attached [3].
The antibiotic properties of tetracyclines are based on
high affinity binding with the bacterial 30S ribosomal
units to inhibit protein synthesis. Importantly, tetracy-
clines have very poor affinity for eukaryotic ribosomes,
and for this reason have relatively few side effects in
eukaryotes. However, some reports suggest that tetracy-
clines may have an anti-inflammatory effect in the lungs.
For example, Fujita et al. have shown that doxycycline
attenuates PMN recruitment in models of lung injury
secondary to LPS, bleomycin or Streptococcus pneumo-
niae pneumonia, and speculate that this is due to inhib-
ition of metalloproteinases [4,5]. If confirmed, these
findings could have important implications for models
using tetracyclines to induce gene expression.
We recently used the rtTA/tetO system to investigate
the role of the adapter protein FADD in LPS-induced
lung injury. In the course of the experiments we also
found a very clear and profound anti-inflammatory effect
of doxycyline. We are publishing these results to illus-
trate the potential confounding effects of doxycyline and




All of the animal experiments were approved by the
Institutional Animal Care Committee of the Univer-
sity of Washington. Mice carrying the reverse tetra-
cycline transactivator under control of the epithelial
cell promoter CCSP (CCSP-rtTA) were kindly pro-
vided by Jeffrey Whitsett. Seventy-two hours prior to
the experiments, some of the mice received doxycyc-
line, 2 mg/mL in the drinking water. On the day of
the experiments, the mice where anesthetized with
inhaled isoflurane, intubated endotracheally with a
20-ga catheter, and given intratracheal installations
of either PBS or LPS, 150 ng/gram. The instillate was
suspended in 2.5% colloidal carbon to allow later confirm-
ation of the extent and distribution of the instillation macro
and microscopically. The mice were returned to their cages
for 24 h, at which point they where euthanized with intra-
peritoneal injections of Beuthanasia D. The thorax was rap-
idly opened, the left hilum was clamped, sutured, and the
left lung was removed and flash frozen in liquid nitrogen.
The right lung was lavaged with three 0.5 mL aliquots of
PBS containing 0.6 mM EDTA (PBS/EDTA) and then fixedin 4% paraformaldehyde at an inflation pressure of 15 cm
of water.Experimental design
The following groups of mice were studied: Mice treated
with PBS only (n = 3), mice treated with doxycycline only
(n = 5), mice treated with LPS only (n = 5), and mice
treated with the combination of LPS and doxycycline
(n = 6).Sample processing
BAL cell counts were performed on a hemacytometer.
Differentials were performed on cytospin preparations
stained with a modified Wright-Giemsa stain (Diff-
Quick, Fischer Scientific Company, Kalamazoo, MI).
Total proteins were measured with the bicinchoninic
acid method (BCA assay, Pierce, Rockford, IL). BAL IgM
was measured using a specific ELISA (Bethyl Laborator-
ies, Montgomery, TX).PMN chemotaxis
C57BL/6 mice were euthanized by exposure to CO2 fol-
lowed by cervical dislocation. The femur and tibia of
both hind legs were isolated and freed of all soft tissue,
and then the ends of both bones were removed. The
femur and tibia were then placed proximal end down in
a 0.6 mL Eppendorf tube, which had been punctured at
its lower tip with an 18-gauge needle and placed inside a
1.5 mL Eppendorf tube. The tubes were spun at 2000 x
g for 30 s and PMNs were then isolated as previously
described [6,7]. After isolation, PMNs were incubated
for 60 min in RPMI containing 1% BSA, calcein-AM
(5 μg/ml; Molecular Probes, Eugene, OR) and PBS, 0.5,
1.0, or 2.0 μg/mL Doxycycline. PMNs were then washed
two times in phosphate buffered saline (PBS) and resus-
pended at a concentration of 1 × 106/mL. PMN chemo-
taxis towards KC (1–333 ng/mL) (PeproTech Inc.,
Rocky Hill, NJ) was then assessed using the Neuro Probe
ChemoTx Disposable Chemotaxis system (Neuro Probe
Inc. Gaithersburg, MD) with the Synergy 4 plate reader
(BioTek, Winooski, VT).Immunoblots
We performed a dot blot for syndecan-1 as previously
described [8]. In brief, dot blot buffer was added to
200 μl of BAL sample (final concentration: 150 mM
NaCl, 50 mM NaOAc, 0.1% Triton-X 100; pH 4.5). Sam-
ples were loaded onto cationic Immobilon Ny + nylon
membranes (Millipore) and immunoblotted with poly-
clonal rabbit anti-mouse syndecan-1 antibody (clone
281.2; 1:1000; BD Biosciences).
Figure 1 Cellular responses. Total BAL PMNs (A), lung homogenate
MPO activity (B) and total BAL alveolar macrophages (AM) (C) in mice
24 h following the intratracheal administration of LPS (150 ng/gm) or
PBS. Some of the mice received doxycycline, 2 mg/kg in the drinking
water starting 72 h prior to the administration of LPS. The BAL PMN
were increased only in the LPS-treated mice without doxy, whereas
lung MPO activity was increased in LPS-treated mice with and without
doxy. This suggests that neutrophils accumulated in the lungs, but did
not enter the alveolar spaces. n: PBS= 3; Doxy = 5, LPS= 5,
LPS+Doxy=6.
Figure 2 Permeability and apoptotic responses. Total BAL
protein (A) and whole lung caspase-3 activity (B) in mice 24 h
following the intratracheal administration of LPS (150 ng/gm) or PBS.
Some of the mice received doxycycline, 2 mg/kg in the drinking
water starting 72 h prior to the administration of LPS. LPS caused an
increase in total BAL protein and in the lung caspase-3 activity,
which was independent of doxy. n: PBS = 3; Doxy = 5, LPS = 5,
LPS +Doxy = 6.
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Figure 3 Tissue responses. Lung tissues from mice treated with intratracheal LPS in the presence or absence of oral doxycycline. The lungs of
mice studied 24 h after the administration of intratracheal LPS showed intra-alveolar inflammatory infiltrates (arrows), which were absent in mice
that received oral doxycycline starting 72 h prior to the administration of LPS. However, there were abundant neutrophils in the alveolar walls of
the mice treated ith LPS and doxy (arrowheads). Note that in either case the alveolar walls remained thin.
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Lung sections were embedded in paraffin, cut into 4 μm
sections, and stained with hematoxylin and eosin. Cryo-
sections were cut fresh, directly placed on the tissue
slide, and immediately visualized in a fluorescence
microscope. PMN were counted on 10 randomly gener-
ated high power fields using morphologic criteria
(nuclear shape, color and size).
Statistical methods
Statistical analysis was performed using ANOVA. When
significant, the ANOVA was followed by the Bonferroni
post hoc analysis. Analysis was performed with Graph-
Pad Prism software. A p-value of less than 0.05 was con-
sidered significant.Figure 4 KC concentrations. BAL concentrations of KC in mice
studied 24 h after the administration of LPS (150 ng/g) or PBS, in the
presence or absence of doxycycline, 2 mg/kg in drinking water
starting 72 h prior to the administration of LPS. There was a
significant increase in KC concentrations in the mice treated with
LPS and doxy. n: PBS = 3; Doxy = 5, LPS = 5, LPS +Doxy = 6.Results
The administration of intratracheal LPS to the lungs of
mice was followed 24 h later by an increase in the total
number of PMN in the BALF (Figure 1-A). However,
when mice were given doxycycline prior to the adminis-
tration of LPS, the neutrophilic response was signifi-
cantly attenuated (p < 0.05). In contrast, lung MPO
activity, indicative of the total content of PMN in the
lungs, was increased in all of the LPS-treated mice, re-
gardless of doxycycline (FIgure 1-C). The number of
BAL macrophages decreased in response to LPS admin-
istration, and remained low when doxycycline was given
prior to LPS (Figure 1-C).
As an assessment of changes in the permeability of the
alveolar-capillary barrier we measured the total protein
concentration in the BALF. There was a modest increase
in BALF total protein in the LPS-treated animals, which
reached significance for the comparison “doxy only” vs
“LPS + doxy” (Figure 2-A). The mice treated with LPS
only had similar BALF total protein concentrations as the
mice treated with LPS and doxy. We also measured
caspase-3 activity as an indicator of apoptosis. There was
a trend towards higher caspase-3 activity in the LPS-
treated mice, which was unaffected by doxy (Figure 2-B).Figure 5 PMN chemotaxis. Percentage of murine bone marrow
PMNs migrating in response to serial concentrations of KC in the
presence of either PBS or 3 different concentrations of doxycycline.
Treatment with doxy did not impair neutrophil chemotaxis to KC
in vitro. n = 3.
Figure 6 BAL syndecan-1. Immunoblots for syndecan-1 in mice
exposed to 72 h of oral doxycycline or to no doxycycline (n = 6/
group). The diagram shows the loading template, with each circle
representing one well containing one sample. The signal is
decreased in the mice treated with doxy.
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the tissue response of animals treated with LPS in the
presence or absence of doxy. Histologically, animals
treated with LPS without doxy showed intra-alveolar
neutrophilic infiltrates, which were absent in the pres-
ence of doxy (Figure 3). The thickness of the alveolar
walls was increased in all animals treated with LPS,
regardless of the presence of doxycycline. In the mice trea-
ted with LPS and doxycycline, fewer PMNs infiltrated the
airspaces than in mice treated with LPS alone, but abun-
dant PMNs remained in the alveolar walls (arrowheads,
Figure 3) and blood vessels. The average number of intra-
alveolar PMN per 400X field was 14± 1.9 in the LPS
group, vs 2 ± 0.6 in the LPS + Doxy group.
PMNs enter the airspaces of the lung in response to
chemotactic gradients, and one of the most important
PMN chemoattractants in mice is the chemokine KC
(CXCL1). Thus, we next investigated the lung BAL con-
centrations of KC. Interestingly, the highest concentra-
tions of KC were seen in the mice treated with LPS and
doxy (Figure 4). We next tested whether doxy impairs
murine PMN chemotaxis against the KC. Murine PMNs
were incubated with three different concentrations of
doxy or PBS, and their chemotaxis towards KC was
measured in a chemotactic chamber. There was no sig-
nificant difference in PMN chemotaxis towards KC at all
of the doxy doses tested, as compared with PMNs incu-
bated with PBS (Figure 5).
Tetracyclines are known to be broad inhibitors of
metalloproteinases, including MMP7 [9,10]. Syndecan-1
is a well-established physiological substrate of MMP7
[8,11]. Thus, we measured cleaved syndecan-1 in the
BAL fluid of a subset of mice as a marker of MMP activ-
ity (Figure 6). We observed a decrease in cleaved
syndecan-1 in the mice treated with doxy, suggesting
decreased metalloproteinase activity (i.e. MMP7).
Discussion
The main finding of this study was that the administra-
tion of doxycycline resulted in a significant reduction in
the total number of BAL PMNs in mice challenged with
LPS. Interestingly, the measurements of lung permeabil-
ity in LPS-treated mice were not affected by doxycycline.
Thus, doxycycline specifically inhibited PMN migration
into the airspaces of the lung without affecting other
parameters of lung injury.
Tetracyclines are known to be broad inhibitors of the
synthesis and activity of metalloproteinases, including
MMP7 (matrilysin) [9,10]. In the lungs, syndecan-1
shedding is MMP-dependent and primarily mediated by
MMP7 [11,12]. Therefore, we used syndecan-1 shedding
as a marker of MMP activity in the lungs in the presence
or absence of doxycycline, and found that doxycycline
reduced the shedding of syndecan-1 into the BAL fluid.PMNs incubated in the presence of doxycycline exhib-
ited similar chemotaxis as compared with PMNs incu-
bated without doxycycline. Because KC, the murine
ortholog of human IL-8 (CXCL8), is one of the most
important PMN chemoattractants in mice, the in vitro
results suggest that a defect in PMN migration or its abil-
ity to sense a chemokine gradient is an unlikely explan-
ation for the decrease in intra-alveolar PMNs seen in the
mice that received doxycycline.
An increasing number of data suggests that tetracyclines
in general, and doxycycline in particular have a powerful
anti-inflammatory effect. In mice, the administration of
doxycycline in the water at a dose of 1.5 mg/kg is protect-
ive in a model of LPS-induced sepsis [13]. Furthermore,
doxycyline at 2.0 mg/kg attenuates lung injury induced by
LPS, doxycycline-resistant S. pneumoniae and bleomycin;
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In humans, doxycycline has been used in the treatment of
lymphangioleiomyomatosis (LAM) [15,16] and decreases
proteinuria in diabetic nephropathy [17], although it was
found to have no effect in osteoarthritis [18]. Clearly,
doxycycline has anti-inflammatory properties that are
independent of its antimicrobial activity.
Our study has relevance for scientists investigating the
role of specific genes using the rtTA/tetO system. If the
proper controls are in place, the rtTA/tetO system is still
a powerful way to design in vivo experiments to test re-
search hypotheses; however, comparing mice treated
with and without doxycycline can be misleading. Instead,
comparisons should be performed between double trans-
genic mice carrying the entire rtTA/tetO system and sin-
gle transgenic mice carrying only the tetO operator, all
in the presence of doxycycline.
Conclusions
In summary, we found that doxycycline doses commonly
used in the rtTA/tetO system resulted in inhibition of
PMN migration into the airspaces. Investigators using
the rtTA/tetO system to study mechanisms of lung in-
jury should proceed with extreme caution and design
studies with the proper controls to account for the con-
founding effects of doxycycline. We conclude that doxy-
cycline is an inhibitor of PMN migration into the
airspaces of the lung.
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